MJP Associates Inc. ADV Invests $201,000 in Bristol-Myers Squibb (NYSE:BMY)

MJP Associates Inc. ADV purchased a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 3,702 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Northwest Financial Advisors acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $34,000. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $40,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $40,000. Finally, Fairman Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $42,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on BMY. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 17th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. BMO Capital Markets reduced their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Finally, Barclays reduced their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Stock Up 2.2 %

Shares of NYSE:BMY traded up $0.89 during midday trading on Friday, reaching $41.93. The company had a trading volume of 35,830,690 shares, compared to its average volume of 13,967,854. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The business’s 50 day moving average price is $43.60 and its 200 day moving average price is $48.43. The stock has a market cap of $85.00 billion, a PE ratio of -13.53, a P/E/G ratio of 13.89 and a beta of 0.43. Bristol-Myers Squibb has a 1-year low of $39.63 and a 1-year high of $65.85.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.05 earnings per share. Research analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 5.72%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.